An observational study in Hypertension, sponsored by AstraZeneca. Completed at 167 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-13.
Sponsored by AstraZeneca · Observational
Non-interventional,observational and retrospective study assessing the therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 2,160 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients aged 18 years or older who has been diagnosed of primary hypertension and/or treated for hypertension.
Exclusion Criteria:
Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
Therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control.
Time frame: 1 Year
Variation in the Percentage of patients with blood pressure controlled and not controlled during a year of follow-up.
Time frame: 1 Year
Clinical profile and cardiovascular risk.
Time frame: 1 Year
Showing the first 100 of 167 sites.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca